Study to Evaluate the Safety and Preliminary Efficacy of Ibrutinib and Pembrolizumab in Patients With Chronic Lymphocytic Leukemia (CLL) or Mantle Cell Lymphoma (MCL)
Phase of Trial: Phase I/II
Latest Information Update: 27 Nov 2018
At a glance
- Drugs Ibrutinib (Primary) ; Pembrolizumab (Primary)
- Indications Chronic lymphocytic leukaemia; Mantle-cell lymphoma
- Focus Adverse reactions
- 16 Nov 2018 Planned End Date changed from 1 May 2022 to 1 Apr 2019.
- 16 Nov 2018 Planned primary completion date changed from 1 May 2019 to 1 Apr 2019.
- 19 Jul 2017 Status changed from not yet recruiting to recruiting.